Year end report 2001


* Sales amounted to SEK 2.071.000 (SEK 975.000 )
* Rights for RescueFlow® acquired in the Nordic countries
* New approvals for RescueFlow® in Europe
* Distribution agreement for RescueFlow® in Asia
* Positive results from pre-clinical studies within BP 04 project
* Patents for BP 04 in the USA and Australia
* Saving plans are implemented
* The net result for the fiscal year amounted to a loss of SEK
23.818.000 (loss SEK 24.765.000); SEK 12.744.000 (SEK 12.034.000) of
which were research and development costs.


Important events after the close of the period

* Patents in 17 European countries for BP 04
* Distribution agreement for RescueFlow® in the Netherlands
* 85% subscription in the new share issue which provides the
company with approximately MSEK 30


Acquisition of...